Abstracts tagged "B cell targeting"

Abstract Number: 32 • 2017 ACR/ARHP Annual Meeting
Longitudinal Associations between Rheumatoid Factor and Ex Vivo Cytokine Production Reveal Novel Mechanistic Insights into Rheumatoid Arthritis
John M. Davis III¹, Cynthia S. Crowson², Keith L. Knutson³, Sara J. Achenbach⁴, Terry M. Therneau⁵, Eric L. Matteson⁶, Sherine E. Gabriel⁷ and Peter J. Wettstein⁸, ¹Division of Rheumatology, Mayo Clinic, Rochester, MN, ²Health Sciences Research, Mayo Clinic College of Medicine and Science, Rochester, MN, ³Immunology, Mayo Clinic, Jacksonville, FL, ⁴Mayo Clinic, Rochester, MN, ⁵Biostatistics, Mayo Clinic, Rochester, MN, ⁶Rheumatology, Mayo Clinic College of Medicine and Science, Rochester, MN, ⁷Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, ⁸Immunology, Mayo Clinic, Rochester, MN
Background/Purpose: Positive rheumatoid factor (RF) and/or anti-citrullinated protein antibodies (ACPA) identify a major rheumatoid arthritis (RA) subgroup, characterized by greater propensity to erosive joint damage…
Abstract Number: 514 • 2017 ACR/ARHP Annual Meeting
BMS-986195, a Novel, Rapidly Acting, Covalent Inhibitor of Bruton’s Tyrosine Kinase: Safety, Pharmacokinetic and Pharmacodynamic Profiles in Healthy Participants
IM Catlett, L Wei, N Zheng, A Liu, B He, I Girgis and M Nowak, Bristol-Myers Squibb, Princeton, NJ
Background/Purpose: Bruton’s tyrosine kinase (BTK) is an attractive, novel therapeutic target for autoimmune disease, as it is required for signal transduction and activation via B-cell…
Abstract Number: 889 • 2017 ACR/ARHP Annual Meeting
Attainment of Low Disease Activity By Patients with Systemic Lupus Erythematosus Starting with High Disease Activity in a 24-Week, Randomized, Placebo-Controlled, Phase IIb Study of Atacicept (ADDRESS II)
Eric F Morand¹, Joan T. Merrill², Amy H. Kao³, Cristina Vazquez-Mateo³, Stephen Wax⁴, Peter Chang⁴, Kishore Pudota³ and David A. Isenberg⁵, ¹Monash University, Melbourne, Australia, ²Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ³EMD Serono Research & Development Institute, Inc. (a business of Merck KGaA, Darmstadt, Germany), Billerica, MA, ⁴EMD Serono Research & Development Institute, Inc. (a business of Merck KGaA, Darmstadt, Germany), BIllerica, MA, ⁵Centre for Rheumatology, Division of Medicine, University College London, London, United Kingdom
Background/Purpose: Low disease activity (LDA) in lupus patients is increasingly a goal of treatment. For instance, Lupus Low Disease Activity State (LLDAS) attainment is associated…
Abstract Number: 12L • 2016 ACR/ARHP Annual Meeting
Efficacy and Safety of Atacicept in Patients with Systemic Lupus Erythematosus: Results of a 24-Week Randomized, Placebo-Controlled, Phase IIb Study
Joan T. Merrill¹, Daniel J. Wallace², Stephen Wax³, Amy Kao⁴, Patricia Fraser⁴, Wai Chin⁴ and David A. Isenberg⁵, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²University of California Los Angeles, Los Angeles, CA, ³EMD Serono, BIllerica, MA, ⁴EMD Serono, Billerica, MA, ⁵University College Hospital, London, London, United Kingdom

Background/Purpose: Atacicept targets B-cell stimulating factors BLyS and APRIL. In the APRIL-SLE trial, atacicept 150 mg was associated with reduced SLE flares in post-hoc analyses.1Methods:…
Abstract Number: 259 • 2016 ACR/ARHP Annual Meeting
Rituximab in Refractory Cardiac Sarcoidosis – Single Center Experience
Megan Krause¹, Leslie T. Cooper Jr.², Panithaya Chareonthaitawee³ and Shreyasee Amin¹, ¹Rheumatology, Mayo Clinic, Rochester, MN, ²Cardiology, Mayo Clinic, Jacksonville, FL, ³Cardiology, Mayo Clinic, Rochester, MN
Background/Purpose: Cardiac sarcoidosis is a life threatening condition for which there is limited data to guide optimal steroid-sparing agents. B-cells have been reported to…
Abstract Number: 764 • 2016 ACR/ARHP Annual Meeting
Atacicept: Integrated Safety Profile from Phase II Randomized Placebo-Controlled Studies in Autoimmune Diseases
Patricia Fraser, Wai Chin and Amy Kao, EMD Serono, Billerica, MA
Background/Purpose: Atacicept, a recombinant fusion protein, targets both BLyS (B lymphocyte stimulator) and APRIL (a proliferation-inducing ligand), B cell activating factors involved in the pathogenesis…
Abstract Number: 940 • 2016 ACR/ARHP Annual Meeting
A Trial of XmAb®5871, a Reversible Inhibitor of CD19+ Cells, in IgG4-Related Disease
John H. Stone¹, Zachary S. Wallace², Cory A. Perugino³, Ana D. Fernandes⁴, Paul A. Foster⁵ and Debra J. Zack⁵, ¹Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, ²Rheumatology Unit, Massachusetts General Hospital, Boston, MA, ³Rheumatology, Massachusetts General Hospital, Boston, MA, ⁴Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Boston, MA, ⁵Xencor, Inc., San Diego, CA
Background/Purpose: IgG4-related disease (IgG4-RD) is an immune-mediated condition responsible for fibro-inflammatory lesions that can lead to irreversible damage. No approved therapies for IgG4-RD exist. We…
Abstract Number: 1087 • 2016 ACR/ARHP Annual Meeting
Nonmemory B Cell Signature Alterations in Belimumab Patients
Karina Marianne D. Torralba¹, Vaneet Sandhu², Abigail Benitez¹ and Sheila Lezcano³, ¹Rheumatology, Loma Linda University, Loma Linda, CA, ²Division of Rheumatology, Loma Linda University, Loma Linda, CA, ³Rheumatology, Loma Linda University Medical Center, Loma Linda, CA
Background/Purpose: Insight into B cell subset dynamics and homeostasis can provide a biological rationale for use of B cell targeted therapies in SLE patients. Using…
Abstract Number: 1091 • 2016 ACR/ARHP Annual Meeting
Synergistic Immunoregulatory Effects of IL-10 and TGF-β on Humoral Immunity
Toshihiko Komai¹, Tomohisa Okamura^1,2, Mariko Inoue¹, Yukiko Iwasaki¹, Kaoru Morita¹, Kazuhiko Yamamoto¹ and Keishi Fujio¹, ¹Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, ²Max Planck-The University of Tokyo Center for Integrative Inflammology, The University of Tokyo, Tokyo, Japan
Background/Purpose: We have previously identified CD4+CD25-Foxp3- regulatory T cells (Treg) that characteristically express lymphocyte-activation gene 3 (LAG3) produce IL-10. Recently we reported that these Treg…
Abstract Number: 1587 • 2016 ACR/ARHP Annual Meeting
A Phase 2a, 4-Week Double-Blind, Proof-of-Concept Efficacy and Safety Study of CC-292 Versus Placebo As Co-Therapy with Methotrexate in Active Rheumatoid Arthritis (RA)
Alan J Kivitz¹, Ramesh Gupta², Guillermo Valenzuela³, Edwin Smith⁴, Quaiser Rehman⁵, Hisham El Kadi⁶, Elizabeth Bretton⁷, Jacob A. Aelion⁸, Anurekh Chadha⁹, John Tesser¹⁰, Douglas Hough¹¹, Shimon Korish¹², Peter H. Schafer¹³, Garth Ringheim¹⁴, Donna Sutherland¹⁵ and Li LI¹⁶, ¹Altoona Arthritis & Osteo Ctr, Duncansville, PA, ²Private Practice, Memphis, TN, ³Integral Rheumatology & Immunology Specialists, Fort Lauderdale, FL, ⁴Rheumatology, Medical University of South Carolina, Charleston, SC, ⁵Rheumatology Clinic of Houston, Houston, TX, ⁶Arthritis & Osteoporosis Associates, Freehold, NJ, ⁷Albuquerque Clinical Trials, Albuquerque, NM, ⁸West Tennessee Research Institute, Jackson, TN, ⁹Department of Rheumatology, Austin Regional Clinic, Austin, TX, ¹⁰Arizona Arthritis and Rheumatology Research, PLLC, Pheonix, AZ, ¹¹Clinical Research, Celgene Corporation, Warren, NJ, ¹²33 Technology Drive, Celgene Corporation, Warren, NJ, ¹³Department of Translational Development, Celgene Corporation, Summit, NJ, ¹⁴Translational Medicine, Celgene Corporation, Summit, NJ, ¹⁵Clinical Research, Celgene Corporation, Summit, NJ, ¹⁶Biostatistics, Celgene Corporation, Summit, NJ
Methods: 47 adult female RA subjects were randomized 1:1 CC-292 375 mg PO daily or placebo (PBO). Subjects were required to have a diagnosis of…
Abstract Number: 2665 • 2016 ACR/ARHP Annual Meeting
Epratuzumab Treatment of Patients with Systemic Lupus Erythematosus and Secondary Sjogren’s Syndrome: An Exploratory Analysis of Phase 3 Studies
Jacques-Eric Gottenberg¹, Thomas Dörner², Hendrika Bootsma³, Valerie Devauchelle-Pensec⁴, Simon Bowman⁵, Gordana Kosutic⁶, Holger Bartz⁷, Marga Oortgiesen⁶, Anthony Shock⁸, Willem Koetse⁶, Catrinel Galateanu⁹, Sabine Bongardt⁷, Xavier Mariette¹⁰ and Caroline Gordon^11,12, ¹Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France, ²Department of Medicine/Rheumatology and Clinical Immunology, Charité University Hospital, Berlin, Germany, ³Department of Rheumatology and Clinical Immunology, University of Groningen, Groningen, Netherlands, ⁴Department of Rheumatology and Unit of Immunology, Brest University Medical School, Brest, France, ⁵Department of Rheumatology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom, ⁶UCB Pharma, Raleigh, NC, ⁷UCB Pharma, Monheim, Germany, ⁸UCB Pharma, Slough, United Kingdom, ⁹UCB Pharma, Brussels, Belgium, ¹⁰INSERM U1184, Université Paris-Sud, Paris, France, Le Kremlin Bicetre, France, ¹¹NIHR/Wellcome Trust Clinical Research Facility, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom, ¹²Rheumatology Research Group, Institute of Inflammation and Ageing, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom
Background/Purpose: The EMBODY 1 (SL0009; NCT01262365) and EMBODY 2 (SL0010; NCT01261793) phase 3 studies investigated the efficacy and safety of epratuzumab (Emab; Immunomedics Inc), a…
Abstract Number: 3033 • 2016 ACR/ARHP Annual Meeting
Safety and Efficacy of Single Dose VAY736 (anti-BAFF-R mAb) in Patients with Primary Sjögren’s Syndrome (pSS)
Thomas Doerner¹, Maximilian Posch², Frank Wagner², Andreas Hueser², Thomas Fischer³, Louise Mooney⁴, Olivier Petricoul⁴, Paul Maguire⁴, Parasar Pal⁵, Julie Doucet⁴, Maciej Cabanski⁴, Esther Kamphausen⁴, Remi Kazma⁴ and Stephen Oliver⁴, ¹Rheumatology and Clinical Immunology, Charité – Universitätsmedizin, Berlin, Germany, ²Charité Research Organisation GmbH, Berlin, Germany, ³Institut für Radiologie und Kinderradiologie, Charité - Universitätsmedizin, Berlin, Germany, ⁴Novartis Pharma AG, Basel, Switzerland, ⁵Novartis Pharma AG, Hyderabad, India
Safety and efficacy of single dose VAY736 (anti-BAFFR mAb) in patients with primary Sjögren’s syndrome (pSS) T Dörner1, M Posch2, F. Wagner2, A Hüser2, T…
Abstract Number: 3105 • 2016 ACR/ARHP Annual Meeting
Relationships Between a Serum Biomarker of B Cell Differentiation and B Cell Activating Factor Suggest Possible Distinct Pathways of Response to Rituximab in Patients with Systemic Lupus Erythematosus
Ricardo Marques¹, Laura Heretiu², David A. Isenberg³, Maria J. Leandro³ and Geraldine Cambridge³, ¹Serviço de Medicina Interna B, Centro Hospitalar Universitário de Coimbra, Coimbra, Portugal, ²Medicine, Centre for Rheumatology, Division of Medicine, University College London, London, United Kingdom, ³Centre for Rheumatology, Division of Medicine, University College London, London, United Kingdom
Background/Purpose: Rituximab (RTX) has been used off-label in refractory SLE with variable clinical outcomes in different cohorts, with no predictive response markers available. However, the…
Abstract Number: 2139 • 2015 ACR/ARHP Annual Meeting
Results of a Phase 1b/2a Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of XmAb®5871 in Patients with Rheumatoid Arthritis (RA)
Debra Zack¹, Maria Jaraczewska Baumann², Mariusz Korkosz³, Gabriella Suljok⁴, Petr Sramek⁵, Bernadette Rojkovich⁶, Stafan Daniluk⁷, Janos Bartalos⁸ and Paul Foster¹, ¹Xencor, Inc., San Diego, CA, ²NZOZ Centrum Medyczne HCP, Poznan, Poland, ³Malopolskie Centrum Medyczne, The University Hospital in Krakow, Krakow, Poland, ⁴Drug Research Center Ltd., Baltonfüred, Hungary, ⁵PRA CZ, Praha, Czech Republic, ⁶Polyclinic of the Hospitaller Brothers of St John of God, Budapest, Hungary, ⁷NZOZ Center of Osteoporosis and Osteoarticular Diseases, Bialystok, Poland, ⁸PRA Hungary Ltd, Budapest, Hungary
Background/Purpose: XmAb®5871 is a humanized Fc engineered monoclonal antibody that binds to the B cell restricted surface antigen CD19 and has enhanced Fc binding to…
Abstract Number: 1093 • 2015 ACR/ARHP Annual Meeting
Activation of Syk-Btk Signal in Peripheral Blood B Cells in Patients with Rheumatoid Arthritis: A Potential Target for Abatacept Therapy
Shigeru Iwata¹, Shingo Nakayamada², Shunsuke Fukuyo¹, Sheau-Pey Wang¹, Satoshi Kubo², Maiko Yoshikawa¹, Kazuyoshi Saito³ and Yoshiya Tanaka³, ¹The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ²First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ³The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan
Background/Purpose: B cells play a pivotal role in the pathogenesis of autoimmune diseases. Although Syk function as a key molecule in BCR signaling, the pathological…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].